WebFeb 13, 2024 · Most cutaneous adverse drug reactions reported in association with chemotherapy, such as a limited maculopapular rash, are considered mild and do not affect the continuation of the treatment. Toxic epidermal necrolysis (TEN), however, is a life-threatening reaction that needs treatment discontinuation. http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Cisplatin_monograph.pdf
Cisplatin (Intravenous Route) Precautions - Mayo Clinic
Eccrine squamous metaplasia is a rare skin reaction. It is also known as syringometaplasia and affects the upper part of the eccrine sweat duct. It presents as non-specific red plaques or a papular, crusted eruption. A distinctive subtype affecting armpits, groin and the sides of the neck has been described. See more Each year, 10.9 million people worldwide are diagnosed with cancer, and this incidence is rising. This increase reflects the world's growing … See more Acral erythema is also known as palmoplantar erythrodysesthesia (PPE) or hand-foot syndrome. It manifests as painful erythema … See more Alopecia (hair loss) is the most common side effect of cancer treatment and often is the most distressing to the patient's self-image. It occurs 7-10 days after treatment and continues to … See more WebSkin problems include a skin rash, dry skin and itching. This usually goes back to normal when your treatment finishes. Your nurse will tell you what products you can use on your skin to help. Hair thinning and hair loss You may have somehair loss or hair thinning. This can be upsetting. Your hair might grow back once treatment has finished. first sentinel bank bluefield virginia
Slowly developing toxic epidermal necrolysis-like reaction
WebSep 15, 2024 · Cisplatin is the prototype platinum coordination complex classified as an alkylating agent and used intravenously in the treatment of several forms of cancer. … WebIn 100 people receiving Bleomycin, Etoposide, Cisplatin, from 4 to 20 may have: Heart attack Swelling of the brain Scarring of the lungs which may cause shortness of breath … WebApr 11, 2024 · Based on the TOPAZ-1 trial, on September 2, 2024, FDA approved duvalizumab combined with gemcitabine and cisplatin as first-line for the treatment of patients with locally advanced or metastatic BTC. 11. ... The most frequent drug-related adverse events were hematological toxicities except rash. camouflage romper plus size